The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

35 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Progress in the development of fatty acid synthase inhibitors as anticancer targets.EBI
University of South Alabama
Fatty Acid Synthase (FASN) Inhibitors as Potential Treatment for Cancer, Obesity, and Liver Related Disorders.EBI
Therachem Research Medilab (India)
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.EBI
Indiana University School of Medicine
Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).EBI
University of Bologna
Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation.EBI
3-V Biosciences
The lipogenesis pathway as a cancer target.EBI
Wayne State University
Fatty Acid synthase inhibitors as possible treatment for cancer: patent highlight.EBI
TBA
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.EBI
Korea Research Institute of Bioscience and Biotechnology
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.EBI
University of Zurich
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.EBI
National Institute of Allergy and Infectious Diseases
Synthesis and evaluation of analogues of S-adenosyl-L-methionine, as inhibitors of the E. coli cyclopropane fatty acid synthase.EBI
Universit£
Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.EBI
Boehringer Ingelheim Pharma
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.EBI
University of London
Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana.EBI
Chinese Academy of Sciences
Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.EBI
Institute of Pharmacology and Toxicology
1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.EBI
Institute of Pharmacology & Toxicology
3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors.EBI
Merck Research Laboratories
Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.EBI
Indiana University School of Medicine
Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).EBI
Forma Therapeutics
Synthesis, biological activities, and docking studies of d-pantolactone derivatives as novel FAS inhibitors.EBI
Third Institute of Oceanography
CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.EBI
Panlabs
Flavanone glycosides from Miconia trailii.EBI
University of Mississippi
Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.EBI
Johns Hopkins University
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.EBI
Janssen Research and Development
A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.EBI
Baylor University
(-)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects.EBI
Yachaytech University
A human fatty acid synthase inhibitor binds ß-ketoacyl reductase in the keto-substrate site.BDB
Glaxosmithkline